NEW YORK — January 1, 2026 — Leads & Copy — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, has announced changes to its Board of Directors following its evolution into a revenue-generating commercial company.
Ms. Jane Bell will retire as Chair but remain on the Board as a non-executive director, having presided over the company’s most transformational period, which included its first U.S. Food & Drug Administration (FDA) approval and successful product commercialization. Mr. Philip Facchina has been unanimously appointed as the new non-executive Chair, and Ms. Lyn Cobley will serve as Chair of the Audit and Risk Committee. Mr. William Burns will continue as Mesoblast Vice-Chair and Chair of the Nomination and Remuneration Committee.
Mr. Facchina, who joined the Mesoblast board in March 2021, brings over 40 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Ms. Cobley, a board member since April 2025, has extensive corporate finance and governance experience at large global institutions and a strong background in strategy, leadership, and regulated industries.
According to outgoing Chair Ms. Bell, the changes reflect a focus on maintaining a high-performing, engaged Board with the right mix of expertise and fresh perspectives. She expressed her support for Mr. Facchina, Ms. Cobley, and the rest of the board as they continue to execute the company’s long-term strategy.
The board undertakes a periodic review of composition, committee assignments, and leadership structure as part of its regular governance process. Mesoblast expects to further strengthen its U.S. commercial expertise in the company in the next twelve months, in line with its commitment to maximizing commercial delivery and shareholder value.
Mesoblast is focused on developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company’s therapies respond to severe inflammation by releasing anti-inflammatory factors that modulate the immune system.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell (MSC) therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older. The company is developing additional cell therapies for indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
Mesoblast has over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These patents provide commercial protection extending through to at least 2044 in all major markets.
The company’s manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. Mesoblast has locations in Australia, the United States, and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).
Paul Hughes, Corporate Communications / Investors, T: +61 3 9639 6036
Emma Neal, Allison Worldwide (Global Media), emma.neal@allisonworldwide.com, T: +1 603 545 4843
Steve Dabkowski, BlueDot Media (Australian Media), steve@bluedot.net.au, T: +61 419 880 486
Source: Mesoblast Limited
